Table 4.
Results of clinical assessments in the three case studies over time
| Assessment | Baseline | 4 wk | 3 mo | 6 mo |
|---|---|---|---|---|
| Patient #1 (54-year-old white man with SPMS, EDSS score 5.5) | ||||
| T25FW | ||||
| Time, sec | 17.1 | 10.3 | 7.5 | 7.6 |
| Speed, m/sec | 0.45 | 0.74 | 1.02 | 1.00 |
| Change in walking speed from baseline,* % | – | +64.4 | +126.7 | +122.2 |
| MSWS-12 score | 83 | 56 | 54 | 58 |
| EQ-5D score | 1.8 | 1.8 | 1.4 | 1.2 |
| FSS score | 5.67 | 5.11 | 4.67 | 4.33 |
| Patient #2 (49-year-old white woman with SPMS, EDSS score 4.0) | ||||
| T25FW | ||||
| Time, sec | 7.1 | 6.6 | 6.2 | 5.9 |
| Speed, m/sec | 1.07 | 1.15 | 1.23 | 1.29 |
| Change in walking speed from baseline,* % | – | +7.5 | +15.0 | +20.6 |
| MSWS-12 score | 77 | 50 | 50 | 48 |
| EQ-5D score | 1.4 | 1.4 | 1.4 | 1.4 |
| FSS score | 6.78 | 6.33 | 4.44 | 5.11 |
| Patient #3 (39-year-old white woman with SPMS, EDSS score 6.5) | ||||
| T25FW | ||||
| Time, sec | 29.4 | 52.7 | NA | NA |
| Speed, m/sec | 0.26 | 0.14 | NA | NA |
| Change in walking speed from baseline,* % | – | −46.2 | NA | NA |
| MSWS-12 score | 65 | 65 | NA | NA |
| EQ-5D score | 1.4 | 2.0 | NA | NA |
| FSS score | 3.56 | 5.78 | NA | NA |
Notes:
Positive (+) percentage change from baseline in walking speed indicates faster walking speed compared with baseline; negative (−) percentage change from baseline indicates slower walking speed compared with baseline. Patients who did not demonstrate clinical benefit of prolonged-release fampridine after 4 weeks of treatment discontinued treatment and were not followed-up on.
Abbreviations: EDSS, Expanded Disability Status Scale; EQ-5D, EuroQoL-5D descriptive system; FSS, Fatigue Severity Scale; mo, month; MSWS-12, 12-item Multiple Sclerosis Walking Scale; NA, not available; sec, second; SPMS, secondary-progressive multiple sclerosis; T25FW, Timed 25-Foot Walk; wk, week.